Dr. Satyam Tatineni, MD

Dr. Tatineni practices at Deaconess Midtown Hospital - Outpatient Therapy in Evansville, Indiana.

Dr. Tatineni's NPI, 1245298066, was assigned on May 2, 2006. Dr. Tatineni holds Indiana license 01041086A.

Dr. Tatineni's primary practice is Deaconess Midtown Hospital - Outpatient Therapy, at 600 Mary St, Evansville, IN 47747. The practice phone is (812) 450-3324.

Dr. Tatineni's primary practice is Deaconess Midtown Hospital - Outpatient Therapy in Evansville, Indiana. Dr. Tatineni is also affiliated with Deaconess Midtown Hospital. The medical group on file is Deaconess Health System. Dmand AI also links Dr. Tatineni to 4 more hospitals, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tatineni practices, 10 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Tatineni's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dmand AI has Dr. Tatineni's licenses on file in 3 states: Indiana, Illinois and Kentucky.

CMS data shows 2,106 Medicare services from Dr. Tatineni across 19 procedure codes in 2024, for 1,231 Medicare patients. Medicare paid $107,494 for them.

CMS counts 1,231 Medicare patients who saw Dr. Tatineni in 2024. The largest group is 65 to 74, with 487 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tatineni's median patient age at 75, with 51% women.

In 2024, Dr. Tatineni wrote 7,923 Medicare Part D claims for 938 patients. 87% of them were for generic drugs. CMS names the drug for 7,691 of them, across 50 drugs with 11 or more claims each, at $935,934 in total drug cost. In 2023, CMS named 7,431 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Tatineni for performance year 2024, reported as part of a group. Dr. Tatineni accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 22 general payments to Dr. Tatineni from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Bristol-Myers Squibb Company paid the most, $157.